EUVIMEDEUVIMED entdecken
Open Access

Molecular signatures define BAP1 -altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes

Philipp Sievers iD, Sonali Arora, Thomas Hielscher, Dilan Savran, Daniel Schrimpf, Rouzbeh Banan, David Vonhören, Stefan Pusch iD, Martin Sill iD, Romain Appay, Hans-Georg Wirsching, Tibor Hortobagyi iD und 26 weitere

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Philipp Sievers und 37 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelber…. Hauptthemen laut MEDLINE: Ubiquitin Thiolesterase, Meningioma, Tumor Suppressor Proteins, Meningeal Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Else Kröner-Fresenius-Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Meningiomas are the most common primary intracranial neoplasms, with highly variable patient outcomes. While most meningiomas are benign, a significant subset recurs postoperatively, presenting substantial treatment challenges. BAP1 gene inactivation has been suggested as a marker for aggressive meningiomas, although its precise molecular and clinical roles remain poorly understood.

Methods

To comprehensively investigate BAP1-altered meningiomas, we used six meningiomas with known BAP1 alterations as a discovery set. Genome-wide DNA methylation profiling of these samples, along 11 151 reference meningiomas, identified a distinct molecular cluster (n = 42) using unsupervised visualization approaches. These tumors were further characterized by DNA/RNA sequencing, histopathological examination, and a retrospective review of clinical data, compared to reference meningioma cohorts, providing a thorough characterization of this rare tumor subtype.

Results

Our integrative analysis revealed BAP1-altered meningiomas as a distinct CNS tumor subtype, characterized by recurrent loss of chromosome 3p21 and driven by various BAP1-inactivating alterations. Although rhabdoid morphology is present in some cases, it is not exclusive and should not be used as a grading criterion. Progression-free survival analysis showed a median of 21 months (95% CI: 12-NA), with a 2-year overall survival rate of 79% (95% CI: 60%-100%), highlighting the aggressive nature of these tumors. Gene expression profiling revealed upregulation of PRC target genes, dysregulated Polycomb signaling, and elevated expression in several cellular and growth factor pathways.

Conclusions

BAP1-altered meningiomas represent a distinct and aggressive CNS tumor subtype associated with PRC dysregulation and recurrent 3p chromosome loss. These findings support the designation “meningioma, BAP1-altered.”

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin ThiolesteraseMeningiomaTumor Suppressor ProteinsMeningeal NeoplasmsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansFemaleMaleMiddle AgedRetrospective StudiesDNA MethylationPrognosisAdultAgedSurvival RateFollow-Up Studies

Stichwörter der Autor:innen

BAP1chromosome 3p lossmeningiomapolycomb signalingrhabdoid

Substanzen

Ubiquitin ThiolesteraseBAP1 protein, humanTumor Suppressor ProteinsBiomarkers, Tumor

Autor:innen und Institutionen

  • Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
  • Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
  • Department of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Division of Pediatric Neurooncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.

ORCID-Profile: Philipp Sievers, Stefan Pusch, Martin Sill, Tibor Hortobagyi, Jens Schittenhelm, Matija Snuderl, Sebastian Brandner, Miriam Ratliff, Wolfgang Wick, Andreas von Deimling, Felix Sahm

Förderung

  • NCI NIH HHS
  • Else Kröner-Fresenius-Stiftung

Zitieren

APA

Sievers, P., Arora, S., Hielscher, T., Savran, D., Schrimpf, D., Banan, R., Vonhören, D., Pusch, S., Sill, M., Appay, R., Wirsching, H. G., Hortobagyi, T., Dohmen, H., Acker, T., Kohlhof-Meinecke, P., Schweizer, L., Wefers, A. K., Harter, P. N., Hartmann, C., …, & Sahm, F. (2025). Molecular signatures define BAP1 -altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf105

Vancouver

Sievers P, Arora S, Hielscher T, Savran D, Schrimpf D, Banan R, et al. Molecular signatures define BAP1 -altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf105

BibTeX
@article{Sievers2025,
  author = {Sievers, Philipp and Arora, Sonali and Hielscher, Thomas and Savran, Dilan and Schrimpf, Daniel and Banan, Rouzbeh and Vonhören, David and Pusch, Stefan and Sill, Martin and Appay, Romain and Wirsching, Hans-Georg and Hortobagyi, Tibor and Dohmen, Hildegard and Acker, Till and Kohlhof-Meinecke, Patricia and Schweizer, Leonille and Wefers, Annika K and Harter, Patrick N and Hartmann, Christian and Beschorner, Rudi and Schittenhelm, Jens and Behling, Felix and Tabatabai, Ghazaleh and Mawrin, Christian and Snuderl, Matija and Maas, Sybren L N and Wesseling, Pieter and Brandner, Sebastian and Korshunov, Andrey and Ratliff, Miriam and Krieg, Sandro M and Wick, Wolfgang and Jones, David T W and Pfister, Stefan M and Holland, Eric C and von Deimling, Andreas and Szulzewsky, Frank and Sahm, Felix},
  title = {Molecular signatures define BAP1 -altered meningioma as a distinct CNS tumor with deregulation of Polycomb repressive complex target genes},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf105}
}
Kostenlos starten →